Critical Contrast: Bioxytran (OTCMKTS:BIXT) vs. enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN) and Bioxytran (OTCMKTS:BIXT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Risk and Volatility

enGene has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for enGene and Bioxytran, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2	8	4	0	2.14
Bioxytran	0	0	0	0	0.00

enGene presently has a consensus target price of $11.05, suggesting a potential upside of 520.53%. Given enGene’s stronger consensus rating and higher probable upside, equities analysts clearly believe enGene is more favorable than Bioxytran.

Valuation and Earnings

This table compares enGene and Bioxytran”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.82
Bioxytran	N/A	N/A	-$2.12 million	($0.02)	-1.24

Bioxytran is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares enGene and Bioxytran’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Bioxytran	N/A	N/A	-737.48%

Institutional and Insider Ownership

64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 70.0% of Bioxytran shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

enGene beats Bioxytran on 6 of the 11 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.